These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11948884)

  • 1. Randomized comparison of Vasoseal and Angioseal closure devices in patients undergoing coronary angiography and angioplasty.
    Shammas NW; Rajendran VR; Alldredge SG; Witcik WJ; Robken JA; Lewis JR; McKinney D; Hansen CA; Kabel ME; Harris M; Jerin MJ; Bontu PR; Dippel EJ; Labroo A
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):421-5. PubMed ID: 11948884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized trial comparing the safety and efficacy of three commercially available closure devices (Angioseal, Vasoseal and Duett).
    Michalis LK; Rees MR; Patsouras D; Katsouras CS; Goudevenos J; Pappas S; Sourla E; Kolettis T; Sioros L; Zotou P; Gartzou-Matsouka P; Sideris DA
    Cardiovasc Intervent Radiol; 2002; 25(5):423-9. PubMed ID: 12132030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plug vs. plug.
    Turi ZG
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):426. PubMed ID: 11948885
    [No Abstract]   [Full Text] [Related]  

  • 4. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty.
    Sanborn TA; Gibbs HH; Brinker JA; Knopf WD; Kosinski EJ; Roubin GS
    J Am Coll Cardiol; 1993 Nov; 22(5):1273-9. PubMed ID: 8227779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of two arterial closure devices, Angioseal and Perclose, in coronary catheter interventions].
    Zhou ZJ; Cui K; Cao SP; Huang Z; Guo ZG; Xiu JC; Hou YQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1767-70. PubMed ID: 22027787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty.
    Sanborn TA; Gibbs HH; Brinker JA; Knopf WD; Kosinksi EJ; Roubin GS
    J Invasive Cardiol; 1999 Sep; 11 Suppl B():6B-13B. PubMed ID: 10745611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel.
    Exaire JE; Tcheng JE; Kereiakes DJ; Kleiman NS; Applegate RJ; Moliterno DJ;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):369-72. PubMed ID: 15736260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review of Randomized Controlled Trials Comparing Manual Compression to Vascular Closure Devices for Diagnostic and Therapeutic Arterial Procedures.
    Cox T; Blair L; Huntington C; Lincourt A; Sing R; Heniford BT
    Surg Technol Int; 2015 Nov; 27():32-44. PubMed ID: 26680377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient tolerance and resource utilization associated with an arterial closure versus an external compression device after percutaneous coronary intervention.
    Juergens CP; Leung DY; Crozier JA; Wong AM; Robinson JT; Lo S; Kachwalla H; Hopkins AP
    Catheter Cardiovasc Interv; 2004 Oct; 63(2):166-70. PubMed ID: 15390237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial experience with a new femoral artery closure device following percutaneous coronary intervention with glycoprotein IIb/IIIa inhibition.
    Ruygrok PN; Ormiston JA; Stewart JT; Webster MW; El Jack S; Simpson-Plaumann S; Kay IP; Chou TM
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):185-91. PubMed ID: 16152652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
    Assali AR; Sdringola S; Moustapha A; Ghani M; Salloum J; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):1-5. PubMed ID: 12508187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular complications after percutaneous coronary intervention following hemostasis with the Mynx vascular closure device versus the AngioSeal vascular closure device.
    Azmoon S; Pucillo AL; Aronow WS; Ebrahimi R; Vozzolo J; Rajdev A; Kalapatapu K; Ro JH; Hjemdahl-Monsen C
    J Invasive Cardiol; 2010 Apr; 22(4):175-8. PubMed ID: 20351388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro).
    Chamberlin JR; Lardi AB; McKeever LS; Wang MH; Ramadurai G; Grunenwald P; Towne WP; Grassman ED; Leya FS; Lewis BE; Stein LH
    Catheter Cardiovasc Interv; 1999 Jun; 47(2):143-7; discussion 148. PubMed ID: 10376492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved clinical effectiveness with a collagen vascular hemostasis device for shortened immobilization time following diagnostic angiography and percutaneous transluminal coronary angioplasty.
    Brachmann J; Ansah M; Kosinski EJ; Schuler GC
    Am J Cardiol; 1998 Jun; 81(12):1502-5. PubMed ID: 9645907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing compression, Perclose Proglide and Angio-Seal VIP for arterial closure following percutaneous coronary intervention: the CAP trial.
    Martin JL; Pratsos A; Magargee E; Mayhew K; Pensyl C; Nunn M; Day F; Shapiro T
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):1-5. PubMed ID: 18098171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of "pre-closure" utilizing the Closer suture-mediated vascular closure device for achievement of hemostasis in patients following coronary interventions: results of the second Perclose Accelerated Ambulation and Discharge (PARADISE II) Trial.
    Nasu K; Tsuchikane E; Sumitsuji S; Tsuji T; Tamai H
    J Invasive Cardiol; 2005 Jan; 17(1):30-3. PubMed ID: 15640537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of hemostatic puncture closing device for hemostasis and early ambulation after coronary angiography and angioplasty: results of a multicenter trial].
    Magosaki N; Hosoda S; Kawagishi N; Yamaguchi T; Sakatani H; Haze K; Itagane H; Otsuka M; Nobuyoshi M; Yokoi H
    J Cardiol; 1999 Sep; 34(3):131-8. PubMed ID: 10500973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
    Exaire JE; Dauerman HL; Topol EJ; Blankenship JC; Wolski K; Raymond RE; Cohen EA; Moliterno DJ;
    Am Heart J; 2004 Jan; 147(1):31-4. PubMed ID: 14691415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angioseal VIP® vs. StarClose SE® closure devices: a comparative analysis in non-cardiological procedures.
    Lucatelli P; Fanelli F; Cannavale A; Corona M; Cirelli C; D'Adamo A; Salvatori FM; Catalano C
    J Cardiovasc Surg (Torino); 2017 Feb; 58(1):80-86. PubMed ID: 24309473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.